PolyNovo

NovoSorb® matrices can often be retained while the infection is treated

1, 2

Robust in the presence of infection 

Offering alternative treatment for complex wounds

3,4,5

Generation of a dermal-like bed over exposed tendons and bones

Designed to minimise contracture over functionally important areas and improve cosmesis

By creating a dermal-like bed for definitive wound closure

Dermal repair to support limb salvage

Bruce Peatey

Focused on our mission to improve patient outcomes and reimagine the standard of care

A bilayer dermal matrix for burns, trauma, and surgical reconstruction. Used in 84,000+ patients globally. FDA-cleared and supported by 450+ clinical publications.

NovoSorb® BTM 

A flexible scaffold for complex wounds. FDA-cleared for up to 6 mm thickness and tunneling wounds. Estimated A$500M addressable market in the U.S.

NovoSorb® MTX 

Invest in PolyNovo

ASX Share Registry

Financial Reports

Webinars

Investor Presentations

ASX Announcements

Half-Year Reports

Corporate Governance

Sustainability

Our Purpose

Leadership

Board of Directors

News

Home

Open Sans

PolyNovo Investor Hub

Hear from PolyNovo CEO, Bruce Peatey, as he shares his priorities to guide the Company’s next phase of growth.

NovoSorb® Technology is the world's first fully synthetic polymer platform for complex wound management, transforming decades of research into biocompatible, versatile wound care and tissue regeneration solutions.

With the proprietary NovoSorb® polymer platform, PolyNovo is delivering strong financial performance, global expansion, and clinical innovation.

Over the past year, we delivered record revenue and profitability, expanded our global footprint to 46 countries, and launched NovoSorb® MTX across key markets. But more importantly, we laid the foundation for the next phase of growth.

With our third manufacturing facility nearing completion and our R&D Innovation Centre completed in FY25, we’re equipped to scale rapidly. Our pipeline is advancing with new applications, representing significant future market opportunities.

We’re preparing for a major regulatory milestone with our FDA Premarket Approval submission for NovoSorb® BTM in full-thickness burns, and we’re actively building momentum in Asia, Europe, and the Americas. Our goal is clear: to become the global leader in regenerative wound care and soft tissue reconstruction.

Thank you for joining us on this journey. The future of healing is being 

PolyNovo’s current product portfolio includes NovoSorb® BTM and NovoSorb® MTX, two complementary dermal scaffolds designed to support tissue regeneration in complex wounds.

Independent clinical evidence supporting the use of NovoSorb® BTM across multiple indications continues to expand, with 402 articles and abstracts published as of FY25.

Group Revenue

Net Profit / (Loss) After Tax

Clinical articles and abstracts

Clinical indications